Significance of ESOPEC for Esophageal/GEJ Adenocarcinoma

Cathy Eng, MD, FACP, FASCO, of Vanderbilt-Ingram Cancer Center, opines on how the ESOPEC study figures to alter the treatment paradigm for patients with esophageal/GEJ adenocarcinoma.

—

Dr. Eng: It is 2 arms. One arm is the cross arm looking at the role of chemotherapy and radiation therapy, which is a standard of care. That is carboplatin plus paclitaxel. The other arm is systemic chemotherapy, the FLOT regimen, which is oxaliplatin and 5-FU and docetaxel.

The reality is that it depends on what the final results will be. The goal of the trial was to determine superiority for the all chemotherapy arm. It will be very interesting.

View her previous comments.